Publicaciones en colaboración con investigadores/as de Hospital Universitario Son Espases (21)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  2. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  3. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells

    British Journal of Haematology

2023

  1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  2. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  2. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  3. Update on the diagnosis of encephalitis

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 41, Núm. 4, pp. 247-257

2021

  1. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Leukemia, Vol. 35, Núm. 1, pp. 245-249

  2. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

    European urology oncology, Vol. 4, Núm. 3, pp. 502-505

  3. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  2. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

    Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554

  3. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

    Leukemia, Vol. 34, Núm. 2, pp. 589-603

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

2017

  1. The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome

    Scientific Reports, Vol. 7, Núm. 1

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

2005

  1. Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia

    Leukemia Research

2004

  1. Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia

    Cancer Genetics and Cytogenetics, Vol. 153, Núm. 1, pp. 16-25